On Monday, Nov. 9, the U.S. Food and Drug Administration ordered makers of every GLP-1 medication, including Ozempic, Wegovy, Mounjaro, and Zepbound, to add a warning about a rare eye condition that can cause permanent vision loss.

In a drug safety communication , the FDA said it is “informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION)” linked to the drug class. The new information will go in the Warnings and Precautions section of each drug’s label.

What NAION Is

NAION happens when blood flow to the front of the optic nerve, known as the optic disc, drops. The FDA describes it as “a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss.” The agency said the underlying cause “is not completely understood.”

Risk factors may include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease, according to the FDA.…